Navigation Links
A ray of light on Cardiology

The angiotensin-converting enzyme (ACE) inhibitor ramipril, used for the treatment of hypertension, can retrieve, and may even prevent, left ventricular hypertrophy (LVH), thereby lowering the risk of stroke and myocardial infarction (MI), a new study has shown.Results from the landmark Heat Outcome Prevention Evaluation (HOPE) study showed the drug to cause reversal and prevention of LVH in a broad range of patients – those with normal or controlled blood pressure, both with and without coronary heart disease.//

The HOPE study compared the effects of the ACE inhibitor in addition to standard therapy with placebo and vitamin E in a sample of about 7,580 high-risk patients with cardiovascular disease.In the HOPE sub-study, conducted by Dr James Chadwik and colleagues from the University of Baltimore, the electrocardiograms of 6,222 patients at baseline and at the end of the 4.5 year-long study were compared for the presence, regression or development of LVH. Cardiovascular outcomes such as MI, stroke and heart failure were also evaluated.

Among 92.9 per cent of the patients, ramipril either prevented or caused gradual regression of LVH, independent of its effect on blood pressure control. Adverse cardiovascular outcomes were also lower among those who did not develop LVH or experienced regression of their LVH, compared with those in which LVH developed or did not regress. However, 91 per cent of the patients who received a placebo experienced prevention or regression of LVH, which the researchers said was “intriguing” but was more likely to be due to other risk factor modifications among the study participants.

Since the regression of LVH found with the drug was independent of blood pressure reduction, the study authors suspect that ACE inhibitors have a direct effect in causing regression.Dr Gregory Bosen, professor of cardiovascular medicine at City Hospital in England, agrees that the research raises important issues. Dr Chadw ik said that monitoring changes in LVH status by ECG might predict outcomes for patients with the condition. “We think we can now reduce the risk of cardiovascular events and death by regression of LVH using ECG markers. The ECG is easily applied and relatively inexpensive.”

'"/>




Related medicine news :

1. Doctors operate upon patients in candlelight- latest from the quake scene
2. “Don’t fear long haul flights!” Vascular surgeon tells travelrs
3. Hazards of sunlight
4. Slightly High BP Poses Health Risk
5. Arterial stiffness prevented by light drinking
6. New light on Cardiology
7. Diet, Sunlight connected to Breast Cancer Risk
8. Dangers of sunlight
9. Nightlights could ward diabetic blindness
10. Unborn babies respond to light
11. Sensitive to bright light? You may have sensitive teeth also
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... ... December 06, 2016 , ... ... of a higher risk of serious health problems, such as cardiovascular illness, according ... Peiman Soleymani of Beverly Hills Periodontics & Dental Implant Center notes that the ...
(Date:12/6/2016)... , ... December 06, 2016 , ... An inventor, from ... utilize a sling, so she invented the patent-pending SLING-VEST. , The SLING-VEST provides an ... offers an improved alternative to traditional slings. As a result, it helps to reduce ...
(Date:12/6/2016)... ... December 06, 2016 , ... Mount Sinai Health System today ... of Neurosurgery, where clinicians can confer and order 3D models for their cases. ... basis with quick turnaround times. This resource will be the first of its ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Touchpoint Solution’s new neuroscience wearable, ... Almost 200 backers pledged more than $25,000 on Kickstarter to bring ... Dr. Amy Serin, an Arizona Neuropsychologist and inventor, says she feels like she stumbled ...
(Date:12/6/2016)... ... December 06, 2016 , ... After 30 years ... Susan Glasgow has announced her retirement from HASA at the end ... more than 4,000 individuals and families with hearing and speech services. She has ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)...  Arcturus Therapeutics, Inc. ("Arcturus" or the "Company"), ... it entered into collaboration with Takeda Pharmaceutical Company ... of NASH and other gastrointestinal (GI) related disorders, ... UNA Oligomer chemistry. The financial terms were not ... and expertise in GI disorders, we are confident ...
(Date:12/6/2016)... , Dec. 6, 2016 A new study ... of 340B (AIR 340B) projects the 340B Drug Pricing Program ... by which time it is expected to exceed $23 billion ... would see 340B purchases surpass current Medicare Part B drug ... The new study – based on analysis of data on ...
(Date:12/6/2016)... Tenn , Dec. 6, 2016  In response ... dependent on opioids every 25 minutes, a respected group ... company that will provide a holistic suite of services ... Based on his own experience trying to ... social entrepreneur Justin Lanning launched 180 ...
Breaking Medicine Technology: